|
Synonyms: IMC-CS4
Compound class:
Antibody
Comment: LY3022855 (IMC-CS4) is a human IgG1 monoclonal antibody designed to target the CSF1R. It is being investigated for its potential anti-neoplastic action. LY3022855 is claimed in patent WO2011123381 [1], by Imclone Llc.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| LY3022855 is being evaluated in Phase 1 clinical trials in patients with a variety of advanced solid tumours, including breast and prostate neoplasms.- see NCT01346358 and NCT02265536. |
| Mechanism Of Action and Pharmacodynamic Effects |
| CSF1R plays an important role as regulator of the development, morphology, survival, and functions of tissue macrophages as well as tumour-associated macrophages (TAMs). CSF1R-targeting antibodies will disrupt macrophage activity in the tumour microenvironment. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01346358 | A Study of IMC-CS4 in Subjects With Advanced Solid Tumors | Phase 1 Interventional | Eli Lilly and Company | ||
| NCT02265536 | A Study of LY3022855 In Participants With Breast or Prostate Cancer | Phase 1 Interventional | Eli Lilly and Company | ||
